Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed. The pump and dump scheme looks to have run its course. Investors are rightfully skeptical of anything coming from PMCB, short of a timeline.
As an immune therapy, atezolizumab would work better with a chemotherapy preconditioning regimen to stimulate the immune system. Atezo is being studied in combination with a host of other agents, including bevacizumab and chemo, but NOT ifosfamide. These are open-label trials. I don't know if there are any data already with metronomic dose ifosfamide in this setting to use as historical controls. Anyway, I agree that the technology has left PMCB behind, and that the mythical clinical trial will still be in mythical discussion stage months from now.
No, he meant down 1.98%
I was asked a question and I answered it. Anybody who has been a holder of PMCB for the long term, and apparently there are a lot on this board, have not had that same 62% return. In fact, most are in the red by a lot unless they're buying the lows and selling at opportune times, which is the way to go with this stock. Without a timeline, it might have a few brief runs upward, but those aren't going to be sustained, and we'll see it continue to drop.
I thought there might be good information exchange on this board about a little known stock. I can easily keep track of the others through public information, meetings that I attend (listening to presentations on trial design and trial results and to the key thought leaders), and biotech sites like FierceBiotech, FirstWord and a couple of others.
To answer Pete's private message, I am here to buy and sell PMCB at opportune times. I originally took a flyer because treatment for advanced pancreatic cancer is an unmet need with a few shots on goal that have missed.
Many people on this board have mentioned that they are longs who have owned PMCB shares for several years. What was the pps 3 years ago? How much could you have made investing elsewhere while waiting for PMCB to go to clinical trials?
I am indeed invested in several. Have seen Kite go up 60% since I bought, Mesoblast has rocketed up in the past 6 months. Hit it pretty big with Ionis. Waiting for Bellicum to turn around. Biggest loser was Novavax...have to stay away from companies that have just one prospect.
Why not? Had you bought Kite-2 1/2 years ago at $29 per share instead of PMCB, you'd be looking pretty good. Same goes with several of these companies.
I cover the industry.
Off the top of my head...Galapagos NV, Alnylam, Mesoblast, Kite, Galectin, Cara, Sarepta, Bellicum, OPKO Health, Ionis, Celldex. All are clinical stage; many have robust pipelines. I'm sure there are more. Some of these, like Kite, have already seen huge run-ups in share price because of success in late phase clinical trials. Some are beaten down (ie, Bellicum) because they've had to offer more shares in order to continue development. But all are stronger than PMCB. We'll see how long this message lasts before it's gone.
I have bought and sold the stock numerous times; that makes me an investor.
None of those companies would make my top 10 list. Certainly not PMCB.
Next week? Another drop in the share price. No timeline for the mythical clinical trial, no pop in the share price. That's Ken Waggoner...working for himself, not the shareholder.
Preclinical work rarely pumps a stock. As I mentioned before, any news from the ACS meeting will be drowned out by the much more important American Association for Cancer Research (AACR) meeting this week.
If you're banking on this for momentum, realize that the work has been conducted in cell lines, which is a long road to clinical potential. Overshadowing this meeting is the Association for Advancement of Cancer Research (AACR) taking place this week, where PMCB has zero presence. A lot of cancer news this week will be coming out of AACR, so I see no catalyst for PMCB here. A few "real" biotechs will see their prices jump based on presentations this week.
This stock is the very definition of a pump and dump. The pps rises when the company makes an announcement about events that just never seem to materialize, like the mythical clinical trial, which has supposedly been in the works for 3 years.
The only thing I would quibble with in your post is the duration of the mythical clinical trial. Data Safety and Monitoring Boards have been known to terminate clinical trials early at interim analyses if a significant benefit is found to a therapy (or if a futility analysis is conducted and finds no chance of a significant benefit if the trial is completed). Assuming, of course, that the mythical trial enrolls actual patients.
I believe you're correct.
The only thing that matters: enrolling patients into a clinical trial.
The day traders have already made money on the stock. :) Even if there's a gap up, if this is the revolutionary technology that some people are claiming it to be, it won't be too late to get into the stock after the fist or second run up.
Any news release that is a year and a half old should be taken with a grain of salt. this company has said several things that never came to fruition.
These are preclinical studies in cell lines. Very very early.
The trial that PMCB will SUPPOSEDLY conduct (many have doubts) has a stop at 6 months to assess results. Not many clinical trials have this stop built in. Because it's a trial of late-stage pancreatic cancer patients whose cancers have progressed despite standard of care, it should become obvious by 6 months whether or not there's a benefit to the ifosfamide/CIAB. At this late stage of the disease, patients typically don't live longer than a few months.
I own quite a few. Like almost all pharma stocks, they have had their trouble during the presidential elections as candidates promised to bring down drug prices. This has continued with President Cheeto's remarks about drug companies getting away with murder. But there are some that I own that have done spectacularly well and other clinical stage biotechs that have held their value really well with promising clinical trial results.
Maybe plenty have already taken a closer look and have decided to pass. Or perhaps they've decided that this stock is good only for buying and selling within a range to make quick money.
That's 2-1/2 years of raking in the cash and doing nothing for shareholders.
In order to get FDA approval, you have to actually conduct a clinical trial!
It's good to have contrasting views on this board. That's what it's for.
That's one ugly chart. Hail to Dr. Makowka!
Selling zone has been established.
Selling a load of shares last week at 0.105 proved to be a great move as well.
0.995 looks to be the new high. Glad I sold a bunch at that level today.
Selling zone looks to be 0.98 to 0.995.
Nobody's losing by not accumulating. Quite the opposite. If a pivotal trial is granted and started, and both are big ifs, there would be plenty of time to accumulate.
Yes, the stock price has stayed depressed since that release. It's difficult for investors to take PMCB seriously when the CEO acts like a baby.
It's going to take another pump-and-dump press release or announcement of a timeline by the company for it go up. Otherwise, it's tread water or fall. The longer without news, the more likely the pps is going to fall, as it should.
That story is 20 months old, and the source is questionable.
.103 or .104 looks like a good selling zone today. Don't know if it will reach .105.
I thought the gift was at .105. Like the loading zone, it must be a moving target.
That seems to be the smart strategy. Don't count on a long-term gain from a company that can't deliver on any of its goals, or even establish timelines. Look for the spikes and dips.